Irish pharmaceutical company Adapt Pharma has filed a complaint against Teva for allegedly infringing a patent centring on its nasal spray Narcan (naloxone hydrochloride).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
21 December 2021 A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
21 December 2021 A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.
21 December 2021 A Delaware Federal Court has upheld some of the validity of challenged claims in two patents related to BioDelivery Sciences’ opioid medication Belbuca, but invalidated others.